Benjamin Weinberg, MD
Hematology & Oncology · Washington, DCNPI 1598064941
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $250,277 of the $325,575 with a category attached, or 76.9%. It is spread thinly across 28 manufacturers, the largest accounting for just 19.6%. Among hematology & oncology clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $927.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sirtex Medical Inc$64K
- Jazz Pharmaceuticals Inc.$57K
- Bayer$50K
- Seagen Inc.$47K
- Taiho Oncology, Inc.$37K
- Lilly USA, LLC$17K
- plus $54K from 22 others
Across 180 payments — averaging $38,603 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Biopharmaceuticals, Inc$4.2M
- Merck$1.7M
- E.r. Squibb & Sons, L.L.C.$308K
- Pfizer$272K
- Janssen Research & Development, LLC$146K
- G1 Therapeutics, Inc.$101K
- plus $266K from 9 others
What the payments were for
- Consulting fees$44,00914%
- Speaking & faculty fees$250,27777%
- Travel & lodging$24,6058%
- Food & beverage$6,5842%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sirtex Medical Inc | 57 | $63,767 |
| Jazz Pharmaceuticals Inc. | 42 | $57,099 |
| Bayer | 65 | $50,459 |
| Seagen Inc. | 38 | $46,728 |
| Taiho Oncology, Inc. | 27 | $36,601 |
| Lilly USA, LLC | 35 | $17,109 |
| Pfizer | 12 | $11,301 |
| Regeneron | 9 | $7,443 |
| Foundation Medicine, Inc. | 4 | $7,096 |
| Partner Therapeutics, Inc. | 14 | $7,047 |
| Novartis | 1 | $5,076 |
| Boehringer Ingelheim International GmbH | 13 | $4,384 |
| Daiichi Sankyo Inc. | 3 | $4,325 |
| Array Biopharma Inc | 7 | $2,048 |
| Boehringer Ingelheim | 1 | $1,740 |
| Blueprint Medicines Corporation | 1 | $1,386 |
| Caris MPI, Inc. | 2 | $450 |
| Exelixis Inc. | 3 | $328 |
| Intera Oncology, Inc | 2 | $281 |
| Ipsen Biopharmaceuticals, Inc | 2 | $218 |
| G1 Therapeutics, Inc. | 1 | $182 |
| AstraZeneca | 3 | $176 |
| Immunocore Limited | 1 | $142 |
| Beigene USA, Inc. | 4 | $66 |
| Janssen Research & Development, LLC | 1 | $38 |
| Tersera Therapeutics LLC | 1 | $35 |
| Angiodynamics, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$325,575 in reported general payments places this provider in the 90th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sunitinib Malate | 13 | $168,997 |
| LonsurfTrifluridine/Tipiracil Hcl | 12 | $81,610 |
| Abiraterone Acetate | 12 | $67,019 |
| CreonLipase/Protease/Amylase | 29 | $48,010 |
| EliquisApixaban | 37 | $33,160 |
| Morphine Sulfate ErMorphine Sulfate | 22 | $893 |
| Oxycodone Hcl | 34 | $758 |
| Prednisone | 19 | $222 |
| Prochlorperazine Maleate | 22 | $182 |
| Ondansetron Hcl | 23 | $136 |
| Pantoprazole Sodium | 22 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Taiho Oncology, Inc.Lonsurf | $36,601 | $81,61012 claims |
| PfizerEliquis | $11,301 | $33,16037 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
- Faysal HarounWashington$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.